Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Biologics Introduces Clinical Policy and Therapeutic Intelligence Office

Published: Wednesday, May 01, 2013
Last Updated: Wednesday, May 01, 2013
Bookmark and Share
Biologics is pleased to announce the launch of its Clinical Policy and Therapeutic Intelligence Office.

The department has been established to advance the company’s clinical expertise efforts as it continues to distinguish itself as a leader in complex disease medical management and pharmacy services, specifically within the oncology sector. Leading this initiative will be Ann Steagall, BSN, RN, OCN, Director of Clinical Policy and Mike James, RPh, PhD, Director of Therapeutic Intelligence.
Primary objectives for the department will be to lead the clinical oversight committee, develop care plans and clinical assessments, and facilitate training for clinical and non-clinical Biologics team members and clients.

“Over the years we have discussed the importance of Biologics leading with our clinical expertise both internally and externally. Additionally, it has long been our objective for Biologics to be considered a teaching organization,” said Stuart Frantz, President & Chief Executive Officer at Biologics. “Combine those two concepts and you have the Clinical Policy and Therapeutic Intelligence Office.”

As Director of Clinical Policy, Ann will lead the coordination of all plan language reviews, an important component of the Care Integration program. She will also continue to serve on the Oncology Board of Advisors.

As Director of Therapeutic Intelligence, Mike will assess all new drug entries and expanded uses which include pipeline monitoring. He will support the development of disease specific whitepapers for client and internal education, and will serve on the Oncology Board of Advisors.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
Antibodies Paving the Way to HIV Vaccine
Researchers uncover factors responsible for the formation of broadly neutralizing HIV antibodies in humans.
Tapping Evolution to Improve Biotech Products
Researchers show how 'ancestral sequence reconstruction' can be used to guide engineering of a blood clotting protein.
Vaccine Against Common Cold Achievable
Researchers suggest that a vaccine against rhinoviruses is possible using variant virus vaccines.
New Weapon Against Hard-to-Treat Bacterial Infections
Using peptides, researchers have been able to prevent drug-resistance bacteria from forming abscesses.
Treating Sepsis with Marine Mitochondria
Mitochondrial alternative oxidase from a marine animal combats bacterial sepsis.
Biomolecular Manufacturing ‘On-the-Go’
Wyss Institute team unveils a low-cost, portable method to manufacture biomolecules for a wide range of vaccines, other therapies as well as diagnostics.
Molecular Switch Aids Immune Therapy
Researchers identify strategy to maximise effectiveness of immune therapy through molecular switch controlling immune suppression.
Novavax RSV F Vaccine Fails Phase 3 Trial
Novavax announces topline RSV F Vaccine data from two clinical trials in older adults.
GSK’s Shingles Vaccine Candidate Shows High Efficacy
The vaccine candidate showed high efficacy against shingles and its complications in adults aged 70yrs+ in phase III study.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!